Sepsis in the tropical Top End of Australia\u27s Northern Territory: disease burden and impact on Indigenous Australians by Davis, Joshua S. et al.
CLOSING THE GAP — RESEARCHSepsis in the tropical Top End of Australia’s Northern Territory: 
disease burden and impact on Indigenous Australians
Joshua S Davis, Allen C Cheng, Mark McMillan, Alex B Humphrey, Dianne P Stephens and Nicholas M AnsteyThe Medical Journal of Australia ISSN:
0025-729X 16 May 2011 194 10 519-
524
©The Medical Journal of Australia 2011
www.mja.com.au
Closing the gap — Research
cardial infarction.1 The epidemiology of sep-
sis has been well described in the US1,2 and
Europe,3,4 but not in tropical regions or for
indigenous populations. The one Australian
study of sepsis epidemiology5 did not
include data from tropical areas of Australia
or on Indigenous status. This study found
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ResuABSTRACT
Objective:  To describe the clinical and epidemiological features of sepsis and severe 
sepsis in the population of the tropical Top End of the Northern Territory of Australia and 
compare these with published estimates for temperate Australia, the United States and 
Europe.
Design, setting and participants:  Prospective cohort study in the major hospital for 
al NT, a region where 27% of the population are Indigenous. We screened all adult 
 years) acute hospital admissions over a 12-month period (6 May 2007 – 5 May 2008) for 
s by standard criteria, and collected standardised clinical data.
 outcome measures:  Population-based incidence of community-onset sepsis and 
e sepsis requiring intensive care unit (ICU) admission; 28-day mortality rate and 
bial epidemiology.
lts:  There were 1191 hospital admissions for sepsis in 1090 patients, of which 604 
(50.7%) were Indigenous people; the average age was 46.7 years. The age-adjusted annual 
population-based incidence of sepsis was 11.8 admissions per 1000 (mortality rate, 5.4%), 
but for Indigenous people it was 40.8 per 1000 (mortality rate, 5.7%). For severe sepsis 
requiring ICU admission, the incidence was 1.3 per 1000 per year (mortality rate, 21.5%), with 
an Indigenous rate of 4.7 per 1000 (mortality rate, 19.3%).
Conclusions:  The incidence of sepsis in the tropical NT is substantially higher than that for 
temperate Australia, the United States and Europe, and these differences are mainly 
accounted for by the high rates of sepsis in Indigenous people. The findings support 
strategies to improve housing and access to health services, and reduce comorbidities, 
alcohol and tobacco use in Indigenous Australians. The burden of sepsis in indigenous 
populations worldwide requires further study to guide appropriate resourcing of health care 
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and preventive strategies.epsis (an acute infection with a sys-
temic response) and severe sepsis (sep-
sis resulting in organ dysfunction) are
very costly and often fatal conditions,1 and
their incidence is increasing.2 Severe sepsis
has been estimated to cause as many deaths
annually in the United States as acute myo-
that the population-based incidence of
severe sepsis requiring admission to an
intensive care unit (ICU) was 0.77 cases per
1000 per year,5 which is comparable with
figures reported from Europe and North
America.6
The tropical Top End of the Northern
Territory of Australia has a high proportion
of Indigenous people, and the NT popula-
tion has a high prevalence of infectious7 and
chronic diseases;8 however, the epidemiol-
ogy of sepsis in this population is unknown.
Similar to many other indigenous peoples,
Australia’s Indigenous population has a
lower life expectancy and a higher burden of
chronic and infectious diseases than non-
Indigenous Australians.9
Most large studies of sepsis epidemiology
are retrospective database analyses based on
discharge coding,1,2,10 which is likely to
significantly underestimate sepsis inci-
dence.11 Most prospective studies are lim-
ited to patients requiring ICU admission,3,5
and are thus not representative of the true
community burden of sepsis requiring hos-
pitalisation. Patients with sepsis that
requires hospital treatment, but not ICU
admission, are common and have a high
mortality rate,1 but these patients are under-
represented in the medical literature.
In this prospective study, we describe the
clinical and epidemiological features of sep-
sis and severe sepsis in tropical northern
Australia, including the population-based
incidence in Indigenous and non-Indigenous
populations, the causative organisms and
outcomes of treatment, and compare these
with published estimates for populations in
temperate Australia, the US and Europe.
METHODS
Setting
Royal Darwin Hospital (RDH) is a 350-bed
teaching hospital in Darwin (latitude
12.5°S) in the tropical Top End of the NT.
RDH is the only hospital for a population of
130 000 over an area of 115 000 km2 (pri-
mary catchment area), and serves as a refer-
ral hospital (including for ICU admission)
for a total population of 170 000 over an
area of 500 000 km2. Indigenous Australians
comprise 27% of the catchment population,
and 30.3% of the population live in
“remote” or “very remote” areas.12
Recruitment and data collection
We undertook a prospective cohort study
comprising every adult ( 15 years) acute
admission to RDH for a 12-month period
from 6 May 2007 to 5 May 2008. In this
period, we evaluated daily every admission
to RDH by admission diagnosis. All patients
whose admission diagnosis could possibly
represent an infection, or was missing,
underwent screening for study inclusion:
examination of the medical record, the
observation chart, and pathology results;
and, where necessary, discussion with the
patient’s treating clinician. In addition, daily
screening rounds were conducted of the
ICU and the emergency department. Finally,
all positive results of blood cultures for the
study period were examined, and those for
episodes not already included in the study
were evaluated. All data were collected by
one of three trained study staff.
All patients who met predefined criteria
for probable or definite infection (see Defini-
tions), in addition to at least two criteria for
the systemic inflammatory response syn-
drome (SIRS),13 were enrolled in the study.
SIRS criteria (see Definitions) were required
to be present concurrently within a 24-hour
period, within the first 48 hours of hospital
admission. Patients’ discharge summaries
and pathology results were assessed at the
time of hospital discharge, and those with a
non-infectious cause of SIRS were subse-
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from this cohort who had pneumonia have
been previously reported as part of an evalu-
ation of pneumonia scoring systems.14
Definitions
Acute admission was defined as any admis-
sion to the acute hospital, excluding day
procedures and attendance for routine
haemodialysis. More than one admission for
sepsis could be counted for the same
patient, but readmission within 14 days of
discharge was not counted as a separate
episode.
Criteria for probable or definite infection
were those used in the PROWESS (Recom-
binant Human Activated Protein C World-
wide Evaluation in Severe Sepsis) study;15
ie, proven infection, or suspected infection,
as evidenced by one or more of the follow-
ing: (i) white cells in a normally sterile body
fluid; (ii) perforated viscus; (iii) radio-
graphic evidence of pneumonia in associa-
tion with the production of purulent
sputum; (iv) a syndrome associated with a
high risk of infection (eg, ascending cholan-
gitis); and (v) a visible site of infection (eg,
cellulitis, abscess).
Criteria for SIRS were two or more of the
following: (i) body temperature  38°C or
 36°C; (ii) heart rate  90 beats/min; (iii)
respiratory rate  20 breaths/min or a PaCO2
 32 mmHg or the use of mechanical venti-
lation; and (iv) a white blood cell count
 12  109/L or  4  109/L or > 10% band
forms.
Severe sepsis was defined as sepsis plus at
least one sepsis-related organ dysfunction
within the first 48 hours after admission, as
defined in the PROWESS study.15
Data management and statistical analysis
After hand-checking of all case record
forms, and data entry (Epidata 3.1, EpiData
Foreningen, Odense, Denmark), 10% of
entries were checked for errors, with a
resulting error rate of < 0.1% of fields.
Denominators for population-based inci-
dence calculations were taken from the Aus-
tralian Bureau of Statistics (ABS) estimated
population figures for June 2007.16 Sepsis
incidence was only calculated for patients
whose current residence was within the
primary catchment area of RDH; the inci-
dence of severe sepsis requiring ICU admis-
sion was calculated using the primary
catchment area for the ICU, a significantly
larger area. Age-adjusted rates were calcu-
lated by the direct method, against the 2001
Standard Australian Population.17 Compara-
tor studies of sepsis epidemiology were
included if they used a similar methodology
and reported comparable data to those
reported in our study.
Factors associated with mortality and
readmission for sepsis were assessed using
logistic regression models with backwards
stepwise selection. All single variables with a
Wald P value of 0.10 were included in the
initial model. Patients with active orders lim-
iting life-sustaining treatment were excluded
from the mortality risk-factor analysis.
Indigenous population estimates were
taken from ABS data from the 2006 cen-
sus.12 Confidence intervals for age-adjusted
rates were calculated using the Poisson dis-
tribution; P values of < 0.05 were considered
significant. All statistical calculations were
performed using Stata v10 (StataCorp, Col-
lege Station, Tex, USA).
Ethics approval
Our study was approved by the Human
Research Ethics Committee of the NT
Department of Health and the Menzies
School of Health Research.
RESULTS
Recruitment and baseline 
characteristics
There were 1191 hospital admissions for
community-onset sepsis in 1090 patients
2 Baseline characteristics of study subjects, by Indigenous status*
Characteristic
Total 
(n = 1191)
Indigenous 
(n = 604)
Non-Indigenous 
(n = 587) P†
Mean age in years (SD) 46.7 (17.4) 43.2 (14.4) 50.2 (19.2) <0.001
Male 624 (52.4%) 261 (43.2%) 363 (61.8%) <0.001
Remote-dwelling‡ 288 (24.2%) 251 (41.6%) 37 (6.3%) <0.001
Hazardous alcohol use§ 339 (46.2%) 246 (62.0%) 93 (27.7%) <0.001
Current smoking¶ 413 (52.1%) 266 (66.5%) 147 (37.4%) <0.001
Chronic renal disease** 140 (11.8%) 114 (18.9%) 26 (4.4%) <0.001
Chronic liver disease** 111 (9.3%) 80 (13.2%) 31 (5.3%) <0.001
Diabetes 285 (23.9%) 188 (31.1%) 97 (16.5%) <0.001
Chronic lung disease** 159 (13.4%) 98 (16.2%) 61 (10.4%) 0.001
Immunosuppression†† 50 (4.2%) 13 (2.2%) 37 (6.3%) 0.001
Malignancy 58 (4.9%) 17 (2.8%) 41 (6.9%) 0.002
* Data are number (%) unless stated otherwise. † P values compare Indigenous with non-Indigenous subjects. 
‡ Remote-dwelling was defined according to the Accessibility / Remoteness Index of Australia.18 § Hazardous 
alcohol use was defined as ethanol ingestion of > 40 g/day for a man or > 20 g/day for a woman.19 The 
denominator for hazardous alcohol use was 733 (Indigenous, 397; non-Indigenous, 336) due to missing data. 
¶ The denominator for current smoking was 793 (Indigenous, 400; non-Indigenous, 393) due to missing data. 
** Definitions for chronic renal, liver and lung disease are those used in the revised Charlson Comorbidity 
Index.20 †† Immunosuppression was defined as HIV infection with CD4 counts of < 200 or use of any of the 
following medications within the past 3 months: prednisolone > 0.5 mg/kg per day (or the equivalent) for 
more than 14 days; immunosuppressive drugs used for bone marrow or solid organ transplantation or cancer 
chemotherapy. ◆
1 Recruitment flowchart
SIRS=systemic inflammatory response syndrome.13 ◆
Acute hospital admissions: 20 969
Eligible admissions: 15 963
Identified for screening: 3882
Met infection criteria: 2193
Met two or more SIRS criteria: 1291
Included in final analysis: 1191
episodes in 1090 patients
Subsequently
excluded: 100
(not infection: 93; duplication
of enrolment: 7)
Aged < 15 years: 5006520 MJA • Volume 194 Number 10 • 16 May 2011
CLOSING THE GAP — RESEARCHover the 12-month period (Box 1): patients’
mean age was 46.7 years, 52.4% were male,
and 50.7% were Indigenous. The Indigenous
population differed substantially from the
non-Indigenous population in demographic
characteristics, comorbidities, and alcohol
and tobacco use (Box 2).
Sepsis incidence
The overall population-based, age-adjusted
incidence (95% CI) of sepsis was 11.8 (11.0–
12.5) admissions per 1000 population per
year compared with 40.8 (37.1–44.5) in
Indigenous people (Box 3, A). The rates for
severe sepsis requiring admission to the ICU
were 1.3 (1.1–1.5) admissions per 1000 pop-
ulation per year overall and 4.7 (3.8–5.7) for
Indigenous people (Box 3, B).
There were a total of 15 963 adult acute
hospital admissions during the study period,
of which the 1191 admissions with sepsis
comprised 7.5%. There were 835 ICU
admissions during the same period, of
which community-onset sepsis accounted
for 190 (22.8%) and community-onset
severe sepsis for 150 (18.0%).
Details of infection
A causative organism was identified in 541
episodes of sepsis (45.4%); Staphylococcus
aureus was the most common causative
organism and Escherichia coli was the most
common blood isolate (Box 4). Overall, the
most common focus of infection was skin
and soft tissue (32.8%) and, among those
3 Population-based incidence of 
sepsis requiring hospital admission 
(A) and severe sepsis requiring ICU 
admission (B) in the tropical Top 
End of the Northern Territory 
compared with other regions*
ICU = intensive care unit. * Data are age-adjusted 
number of incident cases per 1000 population per 
year. Vertical lines at the top of each bar represent 
95% CIs, where available. Data sources: Victoria, 
Australia;21 United States;2 Norway;10 temperate 
Australia;5 France;22 United Kingdom.4 ◆
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4 Causative organisms in patients with sepsis and an identified pathogen*
Causative organism
Overall 
(n = 541)
Blood culture 
positive 
(n = 193)
Community-
acquired 
(n = 404)
Health care-
associated 
indicators† 
(n = 137)
Staphylococcus aureus 136 (25.1%) 33 (17.1%) 99 (24.5%) 37 (27.0%)
MSSA 106 (19.6%) 28 (14.5%) 77 (19.1%) 29 (21.2%)
nmMRSA 28 (5.2%) 4 (2.1%) 22 (5.4%) 6 (4.4%)
mMRSA 2 (0.4%) 1 (0.5%) 0 2 (1.5%)
Escherichia coli 96 (17.7%) 56 (29.0%) 74 (18.3%) 22 (16.1%)
Group A streptococci 48 (8.9%) 12 (6.2%) 35 (8.7%) 13 (9.5%)
Mixed group A streptococci and 
S. aureus‡
29 (5.4%) — 28 (6.9%)§ 1 (0.7%)§
Streptococcus pneumoniae 27 (5.0%) 18 (9.3%) 23 (5.7%) 4 (2.9%)
Pseudomonas spp 19 (3.5%) 2 (1.0%) 10 (2.5%)¶ 9 (6.6%)¶
Mixed anaerobes 19 (3.5%) 1 (0.5%) 16 (4.0%) 3 (2.2%)
Burkholderia pseudomallei 17 (3.1%) 10 (5.2%) 13 (3.2%) 4 (2.9%)
Other β-haemolytic streptococci 14 (2.6%) 9 (4.7%) 8 (2.0%) 6 (4.4%)
Haemophilus spp 13 (2.4%) 2 (1.0%) 11 (2.7%) 2 (1.5%)
Acinetobacter spp 11 (2.0%) 7 (3.6%) 9 (2.2%) 2 (1.5%)
Klebsiella spp 10 (1.8%) 5 (2.6%) 9 (2.2%) 1 (0.7%)
Viridans group streptococci 7 (1.3%) 7 (3.6%) 3 (0.7%) 4 (2.9%)
Neisseria gonorrhoeae 7 (1.3%) 2 (1.0%) 6 (1.5%) 1 (0.7%)
Proteus spp 7 (1.3%) 2 (1.0%) 3 (0.7%) 4 (2.9%)
Influenza virus 6 (1.1%) — 6 (1.5%) 0
Nocardia spp 5 (0.9%) 1 (0.5%) 4 (1.0%) 1 (0.7%)
Milleri group streptococci 5 (0.9%) 2 (1.0%) 4 (1.0%) 1 (0.7%)
Shigella spp 5 (0.9%) — 4 (1.0%) 1 (0.7%)
Other** 60 (11.1%) 24 (12.4%) 39 (9.7%) 21 (15.3%)
Gram-positive bacterium 285 (52.7%) 90 (46.6%) 212 (52.5%) 73 (53.3%)
Gram-negative bacterium 236 (43.6%) 101 (52.3%) 176 (43.6%) 60 (43.8%)
MSSA = methicillin-susceptible S. aureus. mMRSA = multiresistant methicillin-resistant. S. aureus. 
nmMRSA = non-multiresistant methicillin-resistant S. aureus. * An organism was considered to be the primary 
causative organism if it was a pathogen consistent with the clinical presentation, isolated from an appropriate 
specimen collected within the period from 24 hours before to 48 hours after presentation to hospital. Non-
sterile site isolates were only included if they were cultured from deep pus specimens or from purulent 
sputum, with a predominant growth of an organism seen on Gram stain. For each episode, the single most 
important causative organism was selected based on the clinical presentation. † Health care-associated 
indicators included haemodialysis, recent chemotherapy, hospital admission within the previous 90 days, and 
living in a residential care facility.23 ‡ If group A streptococci and S. aureus were both isolated from pus 
specimens, a decision on the principal causative organism was not made, and both were included. § P = 0.005 
and ¶ P = 0.02, comparing community-acquired with health care-associated infections; P values for all other 
organisms were non-significant. ** “Other” includes Enterococcus spp, Enterobacter spp, Neisseria 
meningitidis, Candida spp, Bacteroides spp, Dengue virus, Plasmodium falciparum and Ehrlichia chaffeensis. ◆MJA • Volume 194 Number 10 • 16 May 2011 521
CLOSING THE GAP — RESEARCHwith severe sepsis, pneumonia was most
common (44.8%).
Predictors of mortality
Severity and outcome measures in patients
with severe and non-severe sepsis, including
hospital- and 28-day mortality rates, are
compared in Box 5. Mortality rates were low
by Australian and international standards,
with 28-day mortality rates for sepsis, severe
sepsis and severe sepsis requiring ICU
admission of 5.4%, 17.1% and 21.5%,
respectively; the corresponding mortality
rates in the Indigenous subgroup were
5.7%, 15.9% and 19.3%. There was no
significant difference in mortality rates
between remote-dwelling (6.7%) and
urban-dwelling (5.0%) patients.
On multivariate analysis, the strongest
independent predictors of 28-day mortality
rate were: older age, living in residential
care, the number of SIRS criteria met during
the first 48 hours of hospitalisation, and a
serum albumin level on admission of < 35 g/L
(Box 6). The crude and age-adjusted popula-
tion-based sepsis mortality rates were 44.57
deaths per 100 000 per year and 80.33
deaths per 100 000 per year, respectively.
Hospital admissions for severe sepsis
Of 272 admissions for severe sepsis, 122
(44.9%) were not admitted to the ICU. Of
these 122, 110 (90.2%) had none of the
following factors that might modify the
probability of ICU admission: active orders
limiting life-sustaining treatment, metastatic
cancer, or residence in a nursing home.
Median (interquartile range [IQR]) APACHE
II (Acute Physiology and Chronic Health
Evaluation) scores and 28-day mortality
rates for patients with severe sepsis admitted
only to the ward were 11 (9–13) and 10.7%
compared with 20 (18–22) and 21.5% for
those admitted to the ICU.
Readmissions for sepsis
Of the 1090 individuals in the cohort, 81
were readmitted for sepsis, at least once,
more than 14 days after hospital discharge
but within the 1-year study period. Of the
101 readmission episodes, only 9 (9.0%)
had the same causative organism identified.
The risk of mortality at 1 year of follow-up
was not significantly different in those expe-
riencing at least one readmission (17.2%)
and those who were not readmitted
(12.7%). The only independent risk factors
for readmission after the first episode were:
end-stage renal failure (odds ratio [95% CI]
2.91 [1.35–6.23]), chronic liver disease
(2.73 [1.44–5.21]) and being Indigenous
(1.82 [1.11–2.99]).
Differences between sepsis in 
Indigenous and non-Indigenous 
patients
In Indigenous compared with non-Indige-
nous patients, the focus of infection was more
likely to be pneumonia (38.3% v 23.3%;
P <0.001) or skin and soft tissue infection
(36.0% v 29.5%; P=0.02) and less likely to be
intra-abdominal infection (6.8% v 14.3%;
P <0.001). There was no significant difference
in the causative organisms between Indige-
nous and non-Indigenous patients. Indige-
nous patients were more likely to have severe
sepsis (27.8% v 18.1%; P <0.001) and to
require ICU admission (20.1% v 11.9%;
P < 0.001) than non-Indigenous patients.
However, there was no significant difference
in 28-day mortality rates between Indigenous
and non-Indigenous patients, either for sepsis
(5.7% Indigenous v 5.2% non-Indigenous) or
severe sepsis (15.9% Indigenous v 18.9%
non-Indigenous). Predictors of 28-day mor-
tality rates were not significantly different in
Indigenous compared with non-Indigenous
patients.
DISCUSSION
In this first description of the epidemiology of
sepsis in the tropical Top End of the NT, we
have found that the incidence of sepsis is
fivefold higher than that in temperate Aus-
tralia, the US and Europe. Most of this differ-
ence is accounted for by the extremely high
incidence in Indigenous Australians. Further-
more, sepsis accounted for a substantially
higher proportion of hospital and ICU admis-
sions than has been reported elsewhere.
Compared with temperate areas of Aus-
tralia,5 and the United Kingdom4 and
France,22 the Top End has a significantly
higher population-based incidence of severe
sepsis requiring ICU admission, but this
difference was entirely accounted for by the
extremely high incidence in Indigenous
people (Box 3, B). The rates of sepsis were
about six times higher in our study than
those reported from Victoria, a temperate
region of Australia,21 and the US2 (Box 3,
A), and much of this difference also derives
from the rates in Indigenous people.
Patients in tropical NT with severe sepsis
requiring admission to the ICU were
younger than comparable patients in tem-
perate Australia and had a lower 28-day
mortality rate despite similar APACHE II
and SOFA (sequential organ failure assess-
ment) scores. Among those with severe sep-
sis, the two most common causative
organisms (S. aureus and E. coli) were the
same as those found in studies in temperate
Australia,5 Canada25 and Europe,3 but there
were significantly more gram-negative bac-
teria and fewer fungi among the causative
organisms found in our study than in each
of the other studies.
It is unclear why the incidence of sepsis is
fourfold higher in Indigenous than non-Indig-
5 Severity and outcome of sepsis and severe sepsis episodes*
Severity/outcome measure
Total 
(n = 1191)
Severe 
sepsis† 
(n = 272)
Non-severe 
sepsis 
(n = 919) P‡
Met two SIRS criteria§ 438 (36.8%) 55 (20.2%) 383 (41.7%) < 0.001
Met three or more SIRS criteria§ 753 (63.2%) 217 (79.8%) 536 (58.3%) < 0.001
Required ICU admission 190 (16.0%) 150 (55.1%) 40 (4.4%) < 0.001
APACHE II score (median, IQR) 8 (4–13) 16 (9–22) 6 (3–10) < 0.001
SOFA score (median, IQR) 1 (0–3) 4 (2–7) 1 (0–2) < 0.001
Hospital length of stay in days (median, IQR) 5 (3–11) 8 (4–18) 4 (3–9) < 0.001
ICU length of stay in days (median, IQR) 4 (2–8) 4 (2–9) 3 (1.5–6) 0.19
Hospital mortality¶ 55 (5.0%) 42 (17.1%) 13 (1.5%) < 0.001
28-day mortality** 56 (5.4%) 39 (17.1%) 17 (2.1%) < 0.001
SIRS = systemic inflammatory response syndrome. ICU = intensive care unit. APACHE = Acute Physiology and 
Chronic Health Evaluation. IQR = interquartile range. SOFA = sequential organ failure assessment.
* Data are number (%) unless stated otherwise. † Severe sepsis was defined as sepsis with consequent organ 
dysfunction within the first 48 hours of hospital admission. ‡ P values compare severe sepsis with non-severe 
sepsis. § Criteria as defined by Bone et al13 (see Definitions). ¶ Denominator was 1090 (number of individual 
patients [245 with severe sepsis; 845 with non-severe sepsis]), rather than 1191 (number of admissions). 
** As reliable follow-up after hospital discharge was only available for Northern Territory residents, the 
denominator was 1028 patients (228 with severe sepsis; 800 with non-severe sepsis). ◆522 MJA • Volume 194 Number 10 • 16 May 2011
CLOSING THE GAP — RESEARCHenous people. The design of our study did not
allow us to determine community-based risk
factors for sepsis; however, Indigenous people
in our study had an excess of multiple comor-
bidities, which have been previously shown to
increase the risk of sepsis or severe infections.
These include diabetes, excessive alcohol use,
chronic liver disease and end-stage renal dis-
ease. Other factors that are likely to contribute
to the high burden of sepsis in Indigenous
people include poor housing with a lack of
health hardware (eg, water and sewerage)26
and overcrowding.27
There are no previous published studies
describing the population-based epidemiol-
ogy of sepsis in predominantly indigenous
populations. However, high rates of infec-
tious morbidity have been reported in indig-
enous populations in North America,
Australia and New Zealand.9 The high rate
of sepsis found in our study may reflect the
high incidence of infections in Indigenous
people rather than a tendency to develop
sepsis in response to infection, but this
hypothesis remains to be tested.
In our study, the relatively low mortality
rate in patients admitted to the ICU for
severe sepsis (21.5%) is consistent with
mortality rates previously reported in
patients with severe sepsis from RDH ICU
(21%–25%),28,29 and is lower than the
predicted mortality rate based on this
cohort’s median APACHE II score (25.6%).
This may be explained by the younger
population in tropical NT compared with
temperate Australia and elsewhere; if so,
similar APACHE II scores, despite younger
age, imply either more severe physiological
disturbance or more comorbidities in our
study population compared with other
populations.
There are several potential limitations of
our study. We did not include patients with
sepsis who did not require hospital admis-
sion, making it likely that we have underes-
timated the true incidence of sepsis. Our
population may not be representative of
those in other tropical areas, and it is
unclear whether our results can be general-
ised to these areas. The strengths of our
study include its prospective design, the
capturing of an entire cycle of seasons over a
year, and the inclusion of all patients hospi-
talised for sepsis rather than only patients
admitted to the ICU.
We cannot exclude the possibility that the
higher incidence of sepsis in the Top End of
the NT compared with incidence estimates
from elsewhere reflects methodological dif-
ferences. The comparator studies for sepsis
incidence were all retrospective and based
on discharge coding,2,10,21 a study design
that is likely to substantially underestimate
the true incidence of sepsis.11 This may
explain why we found high rates of sepsis,
but not of severe sepsis requiring ICU
admission, in non-Indigenous people. The
comparator study for severe sepsis requiring
ICU admission in temperate Australia was
prospective,5 and used very similar inclu-
sion criteria and definitions, suggesting that
the observed difference in incidence in the
two studies is a true phenomenon. This
emphasises that the primary finding of our
study is the high rate of sepsis in Indigenous
people, rather than in residents of the tropi-
cal NT in general.
In conclusion, the incidence of sepsis
in the tropical Top End of the NT is
substantially higher than that in temper-
ate Australia and other countries, and
this difference is largely explained by
higher rates in Indigenous people.
Efforts at decreasing this burden should
focus on improving housing and access
to health services, and addressing
comorbidities, and alcohol and tobacco
use. Prospective studies are needed in
indigenous populations globally to
define the burden of sepsis and to inform
appropriate resourcing of health services
and community-based treatment and
prevention strategies.
6 Risk factors for 28-day mortality on univariate and multivariate analysis,* 
grouped according to the PIRO system
Risk factor
Univariate analysis† Multivariate analysis‡
Odds ratios (95% CI)§
Predisposing factors 
Age  45 years¶ 2.7 (1.4–5.3) 2.3 (1.1–4.7)
Age  65 years¶ 6.1 (3.1–12.1) 5.6 (2.7–11.6)
Female sex 0.6 (0.4–0.9) —
Residential care 5.7 (2.2–14.0) 5.7 (1.7–18.0)
Chronic lung disease 3.5 (2.1–6.1) —
Chronic renal disease** 2.5 (1.4–4.6) 2.1 (1.0–4.4)
Infection characteristics
Skin or soft tissue focus†† 0.12 (0.04–0.34) 0.30 (0.10–0.88)
Pneumonia 3.0 (1.8–4.9) —
Bacteraemia 2.9 (1.7–5.0) —
Response to infection
Met three SIRS criteria‡‡ 5.70 (2.18–14.85) 4.1 (1.4–12.0)
Met four SIRS criteria‡‡ 11.4 (4.4–30.0) 5.2 (1.8–15.0)
Albumin < 35 g/L§§ 6.6 (3.8–11.0) 4.9 (2.3–10.0)
Bilirubin 1.01 (1.01–1.02) —
Acute confusion 5.9 (2.9–12.3) 1.3 (1.1–1.6)
Platelet count 0.996 (0.994–0.999) —
Mean arterial pressure 0.966 (0.944–0.988) —
Oxygen saturation 0.859 (0.787–0.936) —
Organ dysfunction
Septic shock 7.1 (4.3–11.8) 2.3 (1.1–4.5)
Acute renal failure 6.9 (3.3–14.0) 3.7 (1.6–8.6)
Acute respiratory failure 4.2 (2.2–8.1) 2.7 (1.3–5.7)
Acidosis 4.3 (2.2–8.4) —
PIRO = predisposition, infection characteristics, response to infection, organ dysfunction.24 
SIRS = systemic inflammatory response syndrome.
* Data were analysed by logistic regression analysis with backward stepwise elimination. † Only significant 
variables are shown. ‡ Only variables remaining in the final model are shown. § Odds ratios are given to one 
or two significant figures except for continuous dependent variables, where three significant figures are used. 
¶ Comparator = age  44 years. ** Defined as usual serum creatinine level > 150 μmol/L, or receiving chronic 
haemodialysis or peritoneal dialysis. †† Compared with all other foci of infection. ‡‡ Met SIRS criteria13 within 
a 24-hour period in the first 48 hours of hospital admission (comparator: two SIRS criteria). §§ Lowest serum 
albumin concentration within first 24 hours of hospitalisation (comparator: albumin level  35 g/L). ◆MJA • Volume 194 Number 10 • 16 May 2011 523
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